CA2231764A1 - Tumor necrosis factor alpha (tnf-.alpha.) inhibiting pharmaceuticals - Google Patents

Tumor necrosis factor alpha (tnf-.alpha.) inhibiting pharmaceuticals Download PDF

Info

Publication number
CA2231764A1
CA2231764A1 CA002231764A CA2231764A CA2231764A1 CA 2231764 A1 CA2231764 A1 CA 2231764A1 CA 002231764 A CA002231764 A CA 002231764A CA 2231764 A CA2231764 A CA 2231764A CA 2231764 A1 CA2231764 A1 CA 2231764A1
Authority
CA
Canada
Prior art keywords
alkyl
hydrogen
tnf
compound
designates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002231764A
Other languages
English (en)
French (fr)
Inventor
Esther Shohami
Ruth Gallily
Raphael Mechoulam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2231764A1 publication Critical patent/CA2231764A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002231764A 1995-09-11 1996-09-10 Tumor necrosis factor alpha (tnf-.alpha.) inhibiting pharmaceuticals Abandoned CA2231764A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL115245 1995-09-11
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals

Publications (1)

Publication Number Publication Date
CA2231764A1 true CA2231764A1 (en) 1997-04-03

Family

ID=11067971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002231764A Abandoned CA2231764A1 (en) 1995-09-11 1996-09-10 Tumor necrosis factor alpha (tnf-.alpha.) inhibiting pharmaceuticals

Country Status (9)

Country Link
US (3) US5932610A (enExample)
EP (1) EP0876143B1 (enExample)
JP (1) JP2000500737A (enExample)
AT (1) ATE331503T1 (enExample)
AU (1) AU708886B2 (enExample)
CA (1) CA2231764A1 (enExample)
DE (1) DE69636308T2 (enExample)
IL (1) IL115245A (enExample)
WO (1) WO1997011668A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
ATE247097T1 (de) * 1998-05-04 2003-08-15 Univ Connecticut Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
BR0009200A (pt) * 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
DE60033834T2 (de) 1999-10-18 2007-11-15 The University Of Connecticut, Farmington Für periphäre cannabinoid-rezeptoren selektive liganden
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001058469A1 (en) * 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
US6531128B1 (en) 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
MXPA02010993A (es) * 2000-05-12 2003-03-10 Genzyme Corp Reguladores de transmision de la tnf-alfa.
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
JP2004501145A (ja) * 2000-06-22 2004-01-15 ファーモス　コーポレイション 向精神作用をもたない新規なカンナビノイド
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
CA2435409A1 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
CA2436133A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
EP1414775B1 (en) * 2001-07-13 2012-12-19 The University of Connecticut Bicyclic cannabinoid
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
PT1562571E (pt) * 2002-11-21 2011-11-25 Genzyme Corp Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica
AU2003291134A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
AU2003302578A1 (en) * 2002-12-04 2004-06-23 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
ZA200802767B (en) * 2005-09-29 2009-09-30 Amr Technology Inc Process for production of delta-9-tetrahydrocannabinol
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
GB0915877D0 (en) 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
WO1994012667A1 (en) * 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage

Also Published As

Publication number Publication date
EP0876143B1 (en) 2006-06-28
IL115245A0 (en) 1995-12-31
DE69636308D1 (de) 2006-08-10
ATE331503T1 (de) 2006-07-15
EP0876143A4 (en) 2001-06-27
AU6942096A (en) 1997-04-17
AU708886B2 (en) 1999-08-12
EP0876143A2 (en) 1998-11-11
WO1997011668A2 (en) 1997-04-03
WO1997011668A3 (en) 1997-05-15
DE69636308T2 (de) 2007-05-31
JP2000500737A (ja) 2000-01-25
IL115245A (en) 2002-12-01
US6331560B1 (en) 2001-12-18
US20020049245A1 (en) 2002-04-25
US6545041B2 (en) 2003-04-08
US5932610A (en) 1999-08-03

Similar Documents

Publication Publication Date Title
US6331560B1 (en) Tumor necrosis factor alpha (TNF-α) inhibiting pharmaceuticals
US4507323A (en) Treatment of psychosexual dysfunctions
JP6076737B2 (ja) 高血圧症の防止及び治療のための組成物並びに方法
US5284867A (en) NMDA-blocking pharmaceutical compositions
US20080300253A1 (en) Treatment of inflammatory disorders with praziquantel
WO1996014064A1 (en) Method and composition for antiviral therapy
EP0578511B1 (en) Spirooxathiolane-quinuclidine derivative, for treating Sjoegren syndrome
FR2622106A1 (fr) Nouvelle application therapeutique de derives du 4h-benzo(4,5)cyclo-hepta(1,2-b)thiophene
JP2650757B2 (ja) 免疫抑制剤として有用な４‐キノリンカルボン酸誘導体
KR0151389B1 (ko) 신질환치료제
EP0534907B1 (en) The use of furanone derivatives for the prevention or treatment of autoimmune diseases
EP0369437B1 (en) Motilin preparation
US6916849B2 (en) Compositions for improving lipid content in the blood
KR20010040413A (ko) 스피카마이신 또는 이것의 유도체를 사용하여 동통을감소시키거나 예방하는 방법
US20060160887A1 (en) Medicinal composition
US20030216357A1 (en) Compositions for improving lipid content in the blood
CA3104916C (en) Pharmaceutical composition for preventing diabetes and use thereof
De Kozak et al. Ginkgo biloba extract (EGb 761) and a platelet-activating factor antagonist protect the retina in experimental autoimmune uveoretinitis
WO2009091134A2 (en) Pharmaceutical composition for sepsis and septic shock
US20010046996A1 (en) Use of a compound for preparing a drug
US12502371B2 (en) Drug for treating and preventing dementia
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
US20070197593A1 (en) Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver
KR20230059075A (ko) 퀴니자린(quinizarin)을 포함하는 당뇨병 예방 또는 치료용 약학적 조성물
JPH0892089A (ja) ドライバジャイナ治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20090910